|
|
Article: BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer.
- Article from:
- PR Newswire
- Article date:
- May 28, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Strategic Collaboration with the Gynecologic Oncology Group -
BRISBANE, Calif., May 28 /PRNewswire/ -- BiPar Sciences, Inc. today announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.
This multi-center, open-label, single-arm study in patients with recurrent or advanced uterine carcinosarcomas will evaluate BSI-201 in combination with standard treatment and is ...
Related newspaper, magazine, and journal articles:
|
|
Article: BiPar Sciences to Present At the 31st CTRC-AACR ...
GlobeNewswire;
December 4, 2008 ;
700+ words
... ... 4, 2008 (GlobeNewswire via COMTEX) -- BiPar Sciences, Inc., a privately held biopharmaceutical ... Convention Center in San Antonio, Texas. About BiPar Sciences and BSI-201 BiPar Sciences, Inc. is a clinical-stage biopharmaceutical ...
|
|